[1]
Keating GM. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Targeted oncology. 2016 Dec:11(6):825-835
[PubMed PMID: 27873136]
[2]
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast cancer research and treatment. 2012 Jun:133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15
[PubMed PMID: 22418700]
[3]
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. International journal of cancer. 2017 Jun 15:140(12):2805-2819. doi: 10.1002/ijc.30691. Epub 2017 Mar 27
[PubMed PMID: 28295308]
Level 1 (high-level) evidence
[4]
Aredo JV, Wakelee HA, Neal JW, Padda SK. Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer treatment and research communications. 2022:30():100497. doi: 10.1016/j.ctarc.2021.100497. Epub 2021 Dec 3
[PubMed PMID: 34920242]
[5]
Li T, Wang S, Ying J, Wang Y, Hu X, Hao X, Xu Z, Xing P, Li J. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic cancer. 2021 Nov:12(21):2924-2932. doi: 10.1111/1759-7714.14156. Epub 2021 Sep 21
[PubMed PMID: 34549528]
[6]
Xu H, Liang Q, Xu X, Tan S, Wang S, Liu Y, Liu L. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature. World journal of surgical oncology. 2021 Nov 18:19(1):330. doi: 10.1186/s12957-021-02444-7. Epub 2021 Nov 18
[PubMed PMID: 34794435]
Level 3 (low-level) evidence
[7]
Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. Journal of neuro-oncology. 2021 Dec:155(3):307-317. doi: 10.1007/s11060-021-03877-6. Epub 2021 Nov 17
[PubMed PMID: 34787778]
[8]
Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochimica et biophysica acta. Reviews on cancer. 2021 Aug:1876(1):188549. doi: 10.1016/j.bbcan.2021.188549. Epub 2021 Apr 22
[PubMed PMID: 33894300]
[9]
Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Targeted oncology. 2019 Feb:14(1):75-83. doi: 10.1007/s11523-018-0612-z. Epub
[PubMed PMID: 30539501]
[10]
Liu X, Suo H, Zhou S, Hou Z, Bu M, Liu X, Xu W. Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells. Cell death & disease. 2021 Jul 22:12(8):728. doi: 10.1038/s41419-021-04011-0. Epub 2021 Jul 22
[PubMed PMID: 34294686]
[11]
Zhu X, Zhou R, Lu Y, Zhang Y, Chen Q, Li Y. Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer. Frontiers in oncology. 2021:11():763035. doi: 10.3389/fonc.2021.763035. Epub 2021 Nov 3
[PubMed PMID: 34804966]
Level 1 (high-level) evidence
[12]
Jiang Y, Fang X, Xiang Y, Fang T, Liu J, Lu K. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current oncology (Toronto, Ont.). 2023 May 28:30(6):5337-5349. doi: 10.3390/curroncol30060405. Epub 2023 May 28
[PubMed PMID: 37366888]
Level 3 (low-level) evidence
[13]
Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical pharmacokinetics. 2017 Mar:56(3):235-250. doi: 10.1007/s40262-016-0440-1. Epub
[PubMed PMID: 27470518]
[14]
Niebecker R, Maas H, Staab A, Freiwald M, Karlsson MO. Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. CPT: pharmacometrics & systems pharmacology. 2019 Apr:8(4):230-239. doi: 10.1002/psp4.12384. Epub 2019 Feb 27
[PubMed PMID: 30681293]
[15]
Liu X, Ma B, Li T, Zhao L. Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Frontiers in pharmacology. 2021:12():698447. doi: 10.3389/fphar.2021.698447. Epub 2021 Oct 13
[PubMed PMID: 34721009]
Level 3 (low-level) evidence
[16]
Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH, American Society of Clinical Oncology Clinical Practice. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20:33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Epub 2015 Aug 31
[PubMed PMID: 26324367]
Level 1 (high-level) evidence
[18]
Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR. Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus. 2018 Jun 14:10(6):e2805. doi: 10.7759/cureus.2805. Epub 2018 Jun 14
[PubMed PMID: 30123727]
Level 3 (low-level) evidence
[19]
Maarof NNN, Alsalahi A, Abdulmalek E, Fakurazi S, Tejo BA, Abdul Rahman MB. Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 2021 Feb 8:13(4):. doi: 10.3390/cancers13040688. Epub 2021 Feb 8
[PubMed PMID: 33567737]
Level 1 (high-level) evidence
[20]
Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, Zhu F, Li C, Xu K, Xiong S, Lu W, Chen Z, Zhong R, Zhao S, Xie Z, Liu J, Liang W, He J. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Critical reviews in oncology/hematology. 2021 Apr:160():103305. doi: 10.1016/j.critrevonc.2021.103305. Epub 2021 Mar 20
[PubMed PMID: 33757838]
Level 1 (high-level) evidence
[21]
Takahashi T, Terazono H, Suetsugu T, Sugawara H, Arima J, Nitta M, Tanabe T, Okutsu K, Ikeda R, Mizuno K, Inoue H, Takeda Y. High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Cancers. 2021 Jul 8:13(14):. doi: 10.3390/cancers13143425. Epub 2021 Jul 8
[PubMed PMID: 34298637]